HomeCompareMRVFF vs ORCC

MRVFF vs ORCC: Dividend Comparison 2026

MRVFF yields 204.19% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRVFF wins by $134.62M in total portfolio value
10 years
MRVFF
MRVFF
● Live price
204.19%
Share price
$0.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$134.64M
Annual income
$68,573,578.28
Full MRVFF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — MRVFF vs ORCC

📍 MRVFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMRVFFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MRVFF + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MRVFF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MRVFF
Annual income on $10K today (after 15% tax)
$17,355.79/yr
After 10yr DRIP, annual income (after tax)
$58,287,541.54/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, MRVFF beats the other by $58,287,540.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MRVFF + ORCC for your $10,000?

MRVFF: 50%ORCC: 50%
100% ORCC50/50100% MRVFF
Portfolio after 10yr
$67.33M
Annual income
$34,286,789.66/yr
Blended yield
50.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

MRVFF
No analyst data
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MRVFF buys
0
ORCC buys
0
No recent congressional trades found for MRVFF or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMRVFFORCC
Forward yield204.19%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$134.64M$21.4K
Annual income after 10y$68,573,578.28$1.04
Total dividends collected$127.03M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: MRVFF vs ORCC ($10,000, DRIP)

YearMRVFF PortfolioMRVFF Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$31,119$20,418.58$11,190$489.61+$19.9KMRVFF
2$92,680$59,382.92$12,229$256.01+$80.5KMRVFF
3$264,456$165,288.68$13,216$130.74+$251.2KMRVFF
4$723,754$440,785.96$14,207$66.02+$709.5KMRVFF
5$1,901,825$1,127,408.73$15,234$33.17+$1.89MMRVFF
6$4,803,662$2,768,709.08$16,317$16.62+$4.79MMRVFF
7$11,675,668$6,535,748.92$17,468$8.32+$11.66MMRVFF
8$27,339,353$14,846,388.95$18,695$4.16+$27.32MMRVFF
9$61,742,649$32,489,540.64$20,006$2.08+$61.72MMRVFF
10$134,638,212$68,573,578.28$21,407$1.04+$134.62MMRVFF

MRVFF vs ORCC: Complete Analysis 2026

MRVFFStock

Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet, a migraine medicine; NeoVisc, an injectable viscosupplement for osteoarthritis; and Resultz, FullMarks, and LAUSBUB for head lice infestations. The company also provides Bezalip SR for patients with high cholesterol or high levels of triglycerides; Proferrin, an iron supplement for the prevention and treatment of iron deficiency; Fiorinal 1 and Fiorinal C1 for the relief of tension-type headaches; Collatamp G for surgical implantation during surgery; PegaLAX, a laxative for the treatment of occasional constipation and irregularity; Mutaflor, a probiotic for the management and relief of chronic constipation and associated abdominal pain and cramps; MoviPrep for the cleansing of the colon in preparation for colonoscopy; and Soriatane to treat psoriasis and other keratinization disorders. In addition, it offers Pennsaid and Pennsaid 2% topical treatments for osteoarthritic pain; Vimovo for relief of arthritis symptoms; SYNERA and RAPYDAN topical patches used to help prevent pain associated with needle sticks and other superficial skin procedures; Yosprala for the prevention of heart attacks and strokes; and Heated Lidocaine/Tetracaine Patch, a topical patch applied prior to painful medical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was incorporated in 1983 and is headquartered in Mississauga, Canada.

Full MRVFF Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this MRVFF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MRVFF vs SCHDMRVFF vs JEPIMRVFF vs OMRVFF vs KOMRVFF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.